作者
Karin C Straathof, Kanchan Rao, Matthias Eyrich, Geoff Hale, Prudence Bird, Eleanor Berrie, Lucinda Brown, Stuart Adams, Paul G Schlegel, Nicholas Goulden, H Bobby Gaspar, Andrew R Gennery, Paul Landais, EG Davies, Malcolm K Brenner, Paul A Veys, Persis Jal Amrolia
发表日期
2009/9/12
期刊
The Lancet
卷号
374
期号
9693
页码范围
912-920
出版商
Elsevier
简介
Background
Stem-cell transplantation can cure primary immunodeficiencies. However, in patients with pre-existing organ toxicity, patients younger than 1 year, and those with DNA or telomere repair disorders, chemotherapy-based conditioning is poorly tolerated and results in major morbidity and mortality. We tested a novel antibody-based minimal-intensity conditioning (MIC) regimen to assess whether this approach allowed curative donor stem-cell engraftment without non-haemopoietic toxicity.
Methods
16 high-risk patients underwent stem-cell transplantation for primary immunodeficiencies with an MIC regimen consisting of two rat anti-CD45 monoclonal antibodies YTH24.5 and YTH 54.12 for myelosuppression, and alemtuzumab (anti-CD52) and fludarabine, and low dose cyclophosphamide for immunosuppression. Donors were matched siblings (n=5), and matched (9) and mismatched (2) unrelated donors …
学术搜索中的文章
KC Straathof, K Rao, M Eyrich, G Hale, P Bird, E Berrie… - The Lancet, 2009